EAGAN, Minn. , Aug. 11, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the financial results for its second quarter ended June 30, 2022 , which shows a strong balance sheet with a solid cash balance, commensurate equity and no debt.
EAGAN, Minn. , July 26, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) today announced a strategic move to further strengthen its business and product offerings by appointing Julia Kirshner , Ph.D., as Chief Scientific Officer. Dr. Kirshner currently serves as Senior Vice President at
EAGAN, Minn. , May 18, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has closed its
EAGAN, Minn. , May 16, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into
EAGAN, Minn. , May 12, 2022 (GLOBE NEWSWIRE) -- The financial results from the first quarter we believe depicts a solid potential for growth in the upcoming period, in accordance with the report by Predictive Oncology Inc. (NASDAQ: POAI) today, disclosing the results for the quarter ended March 31,
EAGAN, Minn. , April 26, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) today announced that Theresa Ferguson has been named Senior Director of Marketing. As Predictive Oncology’s senior marketing leader, Ferguson steps in as the company begins commercialization of its
EAGAN, Minn. , March 31, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the year ended December 31, 2021 , a period defined
Predictive Oncology's Discovery 21 campaign evaluated the ability of its PeDAL® platform to make high-confidence predictions in ovarian tumor samples. Subsequent validation confirmed the accuracy and reproducibility of these predictions. MINNEAPOLIS , March 24, 2022 (GLOBE NEWSWIRE) -- Predictive
MINNEAPOLIS , Jan. 27, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is set to be a first mover in the artificial intelligence (AI) powered drug discovery market that POAI expects will grow to $20 billion in the next three years, reported the Company today in outlining its
MINNEAPOLIS , Jan. 13, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) reported the preliminary results of its Discovery 2021 program today, announcing that its Helomics subsidiary’s evaluation demonstrated their proprietary Artificial Intelligence (AI) program CoRE™ (Computational